The ability to rapidly screen animals for bone mineral content (BMC) and density (BMD) is of greatimportance. Recent advances in instrumentation, including dual-energy X-ray absorptiometry (DXA) andmicro-computed tomography (uCT) have made it possible to determine BMC and BMD in vivo in smallanimal models. The proposed Small Animal Bone Phenotyping Core is a unique facility that has beendeveloped by the Director, Dr. Timothy Nagy, to enable single projects to access state-of-the-art imagingtechniques for the determination of BMC and BMD. The Core will provide all resources, includinginstrumentation and personnel, to carry out its mission. A centralized Core is required due to the cost ofthe instruments and the expertise required in their operations. The Director and personnel of the Corehave demonstrated expertise in the effective use of this technology for the measurement of BMC and BMDin small animals, and are at the forefront of method development and validation of methods in this area.The Core will operate according to a formal quality assurance plan. In addition, the Core will provideextensive education in terms of the appropriate approaches, the limitations of the technology, and theinterpretation of data. Extensive consultation on experimental design (especially animal housing and diet)also will be provided to ensure the generation of informative data.
Two specific aims are proposed for thisinterdisciplinary Core:
Specific Aim 1 : To provided accurate and precise measures of bone mineral content and density insmall animal models. This will be accomplished by providing a centralized core facility containing stateof-the-art instrumentation (DXA and uCT) for in vivo and ex vivo bone imaging.
Specific Aim 2 : Validate new techniques and procedures that will enhance research in bonebiology and allow investigators to ask novel questions while at the same time being assured of theresultant data.The Core has been strategically developed in response to investigator demand and has in the past 4 yearssupported 20 projects instigated by 13 past or current CCBSR investigators, including four Pilot andFeasibility study investigators. It has already stimulated innovative studies in the areas of basic bone cellbiology as well as interdisciplinary studies in the area of the development of gene therapy for bonediseases. It is anticipated that its role in the CCBSR will expand considerably over the next 5 years giventhe enhanced access provided by the P30 funding mechanism, and the increasing use of small animalmodels by the CCBSR investigators. The Core complements the efforts of the other two CCBSR researchCores and several investigators use all three Cores in their ongoing studies.
Showing the most recent 10 out of 138 publications
